33 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
on our goals and progress our novel, first-of-its-kind self-amplifying vRNA immunotherapy candidate, ONCR-021, into the clinic for cancer patients … ; Oncorus’ belief that, following reprioritization, it will be better positioned to deliver on its strategic goals; Oncorus’ plans to discontinue the further
8-K
EX-99.1
bcepva1ru rar2ay
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
424B5
xuoe2oe7pjhm
19 Nov 21
Prospectus supplement for primary offering
4:41pm
8-K
EX-99.1
omyyv1rsqgn2t045uw
4 May 21
Oncorus Reports First Quarter 2021 Financial Results and Provides Business Highlights
7:15am
DEF 14A
4aweyntxpjjtv3u0
28 Apr 21
Definitive proxy
4:06pm
10-K
bgxdwf1
10 Mar 21
Annual report
4:12pm
424B4
3cx6 ud0f
12 Feb 21
Prospectus supplement with pricing info
4:23pm
DRS
EX-10.12
j5lsn
28 Jan 21
Draft registration statement
12:00am
DRS
ghuf23g91fovt1
28 Jan 21
Draft registration statement
12:00am
10-Q
obar477sd
12 Nov 20
Quarterly report
8:01am